The National Organization for Rare Disorders has announced a new, yearlong campaign to raise public awareness of rare diseases. “Do Your Share for Rare” shines a light on people living with a rare disease and provides an opportunity for them to share their story.
The National Organization for Rare Disorders (NORD) has announced a new, yearlong campaign to raise public awareness of rare diseases. “Do Your Share for Rare” shines a light on people living with a rare disease and provides an opportunity for them to share their story.
“For those living with a rare disease, the awareness, education, and support of others is paramount,” Peter L. Saltonstall, president and CEO of NORD, said in a statement. “‘Do Your Share for Rare’ is an attempt at more widespread awareness, which for someone living with a rare disease, means a great deal.”
The campaign is also aiming to prompt people to get involved in a variety of ways, including advocacy, donation, and research.
The announcement of the new campaign kicked off on February 28, which is Rare Disease Day. This year’s Rare Disease Day has the theme of research, and its slogan is “With research, possibilities are limitless.”
There are approximately 7000 known rare diseases, many of which do not have treatments, and research can help increase the understanding of these diseases and identify previously unknown ones.
“Research is key,” according to the official site of Rare Disease Day. “It brings hope to the millions of people living with a rare disease across the world and their families.”
Rare Disease Day 2017 calls upon researchers, universities, students, companies, policy makers, and clinicians to not only do more research, but also recognize the crucial role that patients play in research.
More than 80 countries and hundreds of cities participate in Rare Disease Day. Themes in past years have included patient voice (2016), living with a rare disease (2015), care (2014), solidarity (2013 and 2012), and rare diseases and health inequalities (2011).
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More